XRK3F2 is an inhibitor of the p62-ZZ domain that blunts MM-induced Runx2 suppression in vitro, and induces new bone formation and remodeling in the presence of tumor in vivo.
XRK3F2 blocks TNFα and MM (Multiple myeloma) activation of downstream signaling from the p62-signaling hub. In addition, XRK3F2 also directly decreases osteoclast formation. It directly inhibits cell growth of primary CD138+ MM cells and human MM cell lines in vitro, without negatively affecting the growth of BMSC[1]. XRK3F2 has no effect on non-MM bearing bone. XRK3F2 blocks TNFα but not IL-1β stimulated NFκB phosphorylation in MM patient BMSC and inhibits IκBα degradation by interfering with p-IκBα activation in MM cells treated with TNFα. XRK3F2 also significantly inhibits TNFα-enhanced VCAM-1, IL-6, and RANKL expression by BMSCs from MM patients compared to vehicle. XRK3F2 directly activates caspases 3, 7, and 9 in MM cells and decreases NFκB signaling in MM results in the aggregation of caspase 8 and its downstream effector caspases. Thus, high concentrations of XRK3F2 induce apoptosis in MM cells[2].
In vivo, XRK3F2 induces new bone formation and remodeling in the presence of tumor. The t1/2 of XRK3F2 in mice is 10.3 hours. XRK3F2 induces dramatic, local new bone formation in bones bearing MM in vivo but does not induce new bone formation in bones from the same animals that are not directly inoculated with MM cells. The results demonstrate that XRK3F2 alters the effect of MM on bone[2].
[1] Adamik J, et al. Front Endocrinol (Lausanne). 2018, 9:344. [2] Teramachi J, et al. Leukemia. 2016, 30(2):390-8.